# Tachyon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tachyon-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.tachyontx.com
- Total disclosed funding: $6M
- Latest round: Seed (Sep 23, 2022)
- Investors on record: 3

## About

Based in San Francisco, US, and founded in 2020, Tachyon Therapeutics, Inc., develops therapeutics against new drug targets in cancer biology. In March 2023, Tachyon Therapeutics, Inc. raised USD 11.6 million in venture funding from investors Khosla Ventures, Red Tree Venture Capital, and Veblen Ventures. As of 2023, the company is led by its CEO, Frank Perabo.

Tachyon Therapeutics offers single-cell genomic analysis technology used for the treatment of various cancer types, such as colorectal, esophageal, breast, and lymphoma. The company’s therapeutic solution helps reduce tumor-initiating cancer stem cells responsible for relapses and metastases.

The company plans to use the March 2023 funding to progress the company's portfolio of new cancer drug candidates as well as conduct the Phase 1 clinical trial in advanced solid tumours.

## Funding rounds

- Seed, Sep 23, 2022, $6M — Khosla Ventures, Red Tree Venture Capital, Veblen Ventures

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Seed
- Red Tree Venture Capital (https://capitalatlas.ai/funds/red-tree-venture-capital) — Seed
- Veblen Ventures — Seed